Search results: Sage Journals

Restricted accessResearch articleFirst published October, 2019

The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases?

Michael Gabay

Hospital Pharmacy

Restricted accessResearch articleFirst published January, 1997

The United States Orphan Drug ACT: Challenges and Success

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 1996

Orphan Drug Development Update

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published April, 1999

Orphan Drugs: The United States Experience

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1998

Orphan Drug Development — International Program and Study Design Issues

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1998

Designing Clinical Trials to Study Rare Disease Treatment

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 2010

The National Organization for Rare Disorders (NORD)

Stefanie Putkowski

NASN School Nurse

Restricted accessOtherFirst published January, 2000

The Orphan Drug Act: Provisions and Considerations

Carson R. Reider

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published November, 2009

US regulatory framework for rare plasma protein diseases

Mark Weinstein, Nisha Jain

Pharmaceuticals Policy and Law

Restricted accessResearch articleFirst published September, 2022

A catalyst for change? Orphan drugs and the case of C atalyst v. Becerra

Paul A Braier

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Restricted accessResearch articleFirst published October, 2019

The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases?

Michael Gabay

Hospital Pharmacy

Restricted accessResearch articleFirst published January, 1997

The United States Orphan Drug ACT: Challenges and Success

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 1996

Orphan Drug Development Update

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published April, 1999

Orphan Drugs: The United States Experience

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1998

Orphan Drug Development — International Program and Study Design Issues

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1998

Designing Clinical Trials to Study Rare Disease Treatment

Marlene E. Haffner

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published January, 2010

The National Organization for Rare Disorders (NORD)

Stefanie Putkowski

NASN School Nurse

Restricted accessOtherFirst published January, 2000

The Orphan Drug Act: Provisions and Considerations

Carson R. Reider

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published November, 2009

US regulatory framework for rare plasma protein diseases

Mark Weinstein, Nisha Jain

Pharmaceuticals Policy and Law

Restricted accessResearch articleFirst published September, 2022

A catalyst for change? Orphan drugs and the case of C atalyst v. Becerra

Paul A Braier

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector